Category: Biotech

PharmaDrug Enters Letter Of Intent With Licensed Dealer For Pharma Grade Cocaine

FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.

PharmaDrug Inc (CSE: PHRX) is one step closer to commercializing its biosynthetic, pharmaceutical-grade cocaine. The company as of last week has seen its subsidiary, Securedose Synthetics, sign a letter of intent with a Canadian controlled drug substance licensed dealer.

The letter of intent will enable PharmaDrug to begin full GMP-approved manufacturing once it has finalized the process development for its biosynthetic cocaine product. Technology transfer for the provisionally patented synthesis method is set to begin, in advance of a full agreement for the manufacturing and distribution of the product to support safe supply programs globally.

Once details of the formulation and novel manufacturing process are shared with the licensed dealer, it is expected that feedback will be provided on the application of the process in a commercial-scale manufacturing setting. The final manufacturing and distribution agreement is also expected to include marketing initiatives for both research-based demand as well as demand for safe supply programs.

READ: PharmaDrug Anticipates Biosynthetic Cocaine Commercial-Scale Production In As Little As 12 Months

“We are extremely excited to begin the process of partnering with a Canadian controlled drug substance licensed dealer. The partnership will enable us to prepare for the next steps in SecureDose’s forward strategic and tactical plan by preparing us for the production of a commercial batch, with an eye towards distribution opportunities in the regulated supply chain,” commented Robert Steen, CEO of PharmaDrug.

A full agreement is expected to be signed with the undisclosed licensed dealer closer to the finalization of process development and the completion of a test batch.

PharmaDrug last traded at $0.035 on the CSE.


FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Revive Therapeutics Considers Exploring Bucillamine For Treatment Of Monkeypox

August 29, 2024, 10:31:20 AM

PharmaDrug Subsidiary To Focus Development Of PD-001 On Viral Infectious Diseases

August 28, 2024, 09:52:36 AM

PharmaDrug: Cepharanthine Identified For Potential To Bind To Monkeypox Proteins In Independent Screening

August 21, 2024, 10:26:03 AM

PharmaDrug Joint Venture Receives Approval For Phase 1 Clinical Trial

August 19, 2024, 09:08:46 AM

Cytophage Develops Freeze-Dried Phage Tablets For Poultry

August 15, 2024, 02:56:00 PM

Phage Therapy’s Rising Demand: Cytophage at the Forefront with Dr. Steven Theriault

August 15, 2024, 02:04:00 PM

Cassava Sciences Replaces Entire Management Team Amid Data Falsification Scandal

July 18, 2024, 11:08:00 AM

Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company

June 21, 2024, 08:45:08 AM

FDA Panel Rejects MDMA for PTSD Amid Safety and Methodology Concerns In The Trials

June 7, 2024, 12:46:00 PM

Cytophage Adds 30-Year Biotech Exec To Its Board

May 27, 2024, 09:09:36 AM

PharmaDrug Enters Letter Of Intent With Licensed Dealer For Pharma Grade Cocaine

May 23, 2024, 08:22:42 AM

PharmaDrug Anticipates Biosynthetic Cocaine Commercial-Scale Production In As Little As 12 Months

May 13, 2024, 08:55:00 AM
Video Articles

Bell Q3 Earnings: Massive Impairments. Guidance Cuts. A Mess.

Alamos Gold Q3: Record Revenue & Production Amid Rising Costs

The Junior Mining Market Is Back

Recommended

Germany Looks To Modernize Military Recruitment But Stops Short of Conscription

First Majestic Silver Posts Topline Revenue Of $146.1 Million In Q3 2024